B-hPD-1/hLAG3 Mice

Basic Information

Strain Name
C57BL/6-Pdcd1 tm1(PDCD ) Lag3 tm1(LAG3) /Bcgen
Stock Number
120520
Common Name
B-hPD-1/hLAG3 mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
PD-1(Programmed death-1); LAG3(Lymphocyte activation gene 3,CD223)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous

Targeting Strategy

 

Details

Phenotype

Protein Expression Analysis

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hLAG3 mice were analyzed by flow cytometry. Mouse LAG3+ T cells were detectable in both WT C57BL/6 and the homozygous B-hPD-1/hLAG3 mice, while human LAG3+ T cells were detectable in the homozygous B-hPD-1/hLAG3 mice. This might result from the cross-recognition of hLAG3 by anti-mLAG3 antibodies.

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hLAG3 mice were analyzed by flow cytometry. Mouse PD-1+ T cells were detectable in the WT C57BL/6 mice, while human PD-1+ T cells were detectable in the homozygous B-hPD-1/hLAG3 mice.

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hLAG3 mice were analyzed by flow cytometry. Mouse PD-1+/LAG3+ T cells were detectable in the WT C57BL/6 mice, while mouse LAG3+ T cells were detectable in the homozygous B-hPD-1/hLAG3 mice, which might result from the cross-recognition of hLAG3 by anti-mLAG3 antibodies.

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hLAG3 mice were analyzed by flow cytometry. Human PD-1+/LAG3+ T cells were detectable in homozygous B-hPD-1/hLAG3 mice.

Application

Combination therapy of PD-1 (Keytruda) mAb and L AG3 mAb

B-hPD-1/hLAG3 Mice

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hLAG3 mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=6). Anti-hLAG3 antibody shows no inhibitory effects, while the anti-hPD-1 antibody Keytruda shows modest tumor growth inhibition. On the other hand, combination of anti-hLAG3 antibody and the anti-hPD-1 antibody Keytruda shows more significant inhibition when compared to single Ab treatment. B-hPD-1 /hLAG3 mouse model is a powerful tool for in vivo efficacy evaluation of hPD-1 and hLAG3 antibody combination therapy. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

  1. Nat Commun. 2017 Feb 6;8:14369. doi: 10.1038/ncomms14369.
  2. EMBO J. 1992 Nov;11(11):3887-95.
  3. J Exp Med. 2000 Oct 2;192(7):1027-34.
  4. Science. 2001 Jan 12;291(5502):319-22.
  5. 1. J Exp Med. 1990 May 1;171(5):1393-405.
  6. 2.Proc Natl Acad Sci U S A. 1997 May 27;94(11):5744-9.
Back to top